Pharmacokinetics of selective estrogen receptor modulators

Clinical Pharmacokinetics

Volumn 42, Issue 4, 2003, Pages 361-372

  Morello, Karla C ^a   Wurz, Gregory T ^a   DeGregorio, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; ARZOXIFENE; COLESTYRAMINE; CYTOCHROME P450; DEAMINOHYDROXYTOREMIFENE; DRUG METABOLITE; LETROZOLE; NORTAMOXIFEN; NORTOREMIFENE; OSPEMIFENE; RALOXIFENE; RIFAMPICIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; WARFARIN;

AGE; ANTINEOPLASTIC ACTIVITY; BIOAVAILABILITY; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; FOOD DRUG INTERACTION; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; LIVER DYSFUNCTION; LUNG EMBOLISM; NAUSEA; OSTEOPOROSIS; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RASH; RETINA VEIN; REVIEW; STEADY STATE; STOMATITIS; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VASOMOTOR DISORDER; VEIN THROMBOSIS; VOMITING;

AGE FACTORS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; KIDNEY DISEASES; LIVER DISEASES; OSTEOPOROSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0037255847     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342040-00004     Document Type: Review

References (73)

1. Snyder KR, Sparano N, Matinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm 2000 Sep; 57 (18): 1669-78
2. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1270a) in breast cancer. J Steroid Biochem Mol Biol 2001 Jun; 77 (4-5): 271-9
3. Wenger NK, Grady D. Postmenopausal hormone therapy, SERMs, and coronary heart disease in women. J Endocrinol Invest 1999 Sep; 22 (8): 616-24
4. Taras TL, Wurz GT, Linares GR. et al. Clinical pharmacokinetics of toremifene. Clin Pharmacokinet 2000 Nov; 39 (5): 327-34
5. Marttunen MB, Hietanen P, Tiitinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998 Apr; 83 (4): 1158-62
6. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound. PC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000 Feb: 141 (2): 809-20
7. Sato M, Turner CH, Wang T, et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998 Oct; 287 (1): 1-7
8. Fuchs WS, Leary WP, van der Meer MJ, et al. Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women. Arzneimittel Forschung 1996 Apr; 46 (4): 418-22
9. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 1998 Jan; 16 (1): 348-53
10. Fisher B, Costantino JP, Lawrence D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998 Sep; 90 (18): 1371-88
11. Legha SS. Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988 Aug; 109 (3): 219-28
12. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992 Mar; 326 (13): 852-6
13. Saarto T, Blomqvist C, Ehnholm C. et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996 Feb; 14 (2): 429-33
14. Gershanovich M, Garin A, Baltina D, et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 1997 Sep; 45 (3): 251-62
15. Holli K. Adjuvant trials of toremifene vs tamoxifen: the European experience. Oncology 1998 Mar; 12 (3 Suppl. 5): 23-7
16. Gams R. Phase III trials of toremifene vs tamoxifen. Oncology 1997 May; 11 (5 Suppl. 4): 23-8
17. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Adjuvant Breast and Bowel Project (NSAPB-14). J Natl Cancer Inst 1994 Apr; 86 (7): 527-37
18. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997 Dec; 337 (23): 1641-7
19. Muchmore DB. Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 2000; 5 (5): 388-92
20. Meunier PJ, Vignot E, Garnero P. et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 1999; 10 (4): 330-6
21. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999 Aug; 282 (7): 637-45
22. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998 May; 279 (18): 1445-51
23. Scott JA, Camara CC, Early JE. Ratoxifene: a selective estrogen receptor modulator. Am Fam Physician 1999 Sep; 60 (4): 1131-9
24. DeGregorio MW, Wurz GT, Taras TL, et al. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 2000 Sep; 56 (6-7): 469-75
25. Viopio SK, Komi J, Kangas L, et al. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index and hormonal status in healthy postmenopausal women. Maturitas 2002; 43: 207-14
26. Münster PN, Buzdar A, Dhingra K, et al. Phase I study of a third-generation selective estrogen receptor modulator. LY353381.HCL, in metastatic breast cancer. J Clin Oncol 2001 Apr; 19 (7): 2002-9
27. Schafer JM, Lee ES, Dardes RC, et al. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. Clin Cancer Res 2001 Aug; 7 (8): 2505-12
28. Guelen PJM, Stevenson D, Briggs RJ, et al. The bioavailability of Tamoplex (tamoxifen): Part 2. a single dose cross-over study in healthy male volunteers. Methods Find Exp Clin Pharmacol 1987 Oct; 9 (10): 685-90
29. Buckley MMT, Goa KL. Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989 Apr; 37 (4): 451-90
30. Kemp JV, Adam HK, Wakeling AE, et al. Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 1983 Jul; 32 (13): 2045-52
31. Wilkinson P, Ribeiro G, Adam H, et al. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer. Cancer Chemother Pharmacol 1980; 5 (2): 109-11
32. Anttila M, Laakso S, Nyländen P, et al. Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther 1995 Jun; 57 (6): 628-35
33. Wiebe VJ, Benz CC, Shemano I, et al. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 1990; 25 (4): 247-51
34. Kohler P, Hamm JT, Wiebe VJ, et al. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res Treat 1990 Aug; 16 Suppl. 1: S19-26
35. Evista® (raloxifene hydrochloride): package insert. Indianapolis (IN): Lilly, 1998
36. Wiebe VJ, Benz CC, DeGregorio MW. Clinical pharmacokinetics of drugs used in the treatment of breast cancer. Clin Pharmacokinet 1988 Sep; 15 (3): 180-93
37. Bonanni B, Harriet J, Gandini S, et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat 2001 Sep; 69 (1): 21-7
38. Tukker JJ, Blankenstein MA, Nortier JWR. Comparison of bioavailability in man of tamoxifen after oral and rectal administration. J Pharm Pharmacol 1986 Dec; 38 (12): 888-92
39. Anttila M, Valavaara R, Kivinen S, et al. Pharmacokinetics of toremifene. J Steroid Biochem 1990 Jun; 36 (3): 249-52
40. Herrlinger C, Braunfels M, Fink E, et al. Pharmacokinetics and bioavailability of tamoxifen in healthy volunteers. Int J Clin Phamacol Ther Toxicol 1992 Nov; 30 (11): 487-9
41. Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxyN-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989 Apr; 49 (8): 2175-83
42. Wiseman LR, Goa KL. Toremifene: a review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 1997 Jul; 54 (1): 141-60
43. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 1980 Jun-Jul; 64 (6-7): 765-73
44. Sipilä H, Näntö V, Kangas L, et al. Binding of toremifene to human serum proteins. Pharmacol Toxicol 1988 Jul; 63 (1): 62-4
45. Wilking N, Appelgren LE, Carlstrom K, et al. The distribution and metabolism of 14C-labelled tamoxifen in spayed female mice. Acta Pharmacol Toxicol 1982; 50 (3): 161-8
46. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissue during steady-state treatment. Cancer Res 1991 Sep; 51 (18): 4837-44
47. Fromson JM, Sharp DS. The selective uptake of tamoxifen by human uterine tissue. J Obstet Gynaecol 1974 Apr; 81 (4): 321-3
48. Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (I.C.I. 46,474): II. in female patients, Xenobiotica 1973 Nov; 3 (11): 711-4
49. Lønning PE, Lien EA, Lundgren S, et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992 May; 22 (5): 327-58
50. Kangas L, Haaparanta M, Paul R, et al. Biodistribution and scintigraphy of 11C-toremifene in rats bearing DMBA-induced mammary carcinoma. Pharmacol Toxicol 1989 Apr; 64 (4): 373-7
51. Sotaniemi EA, Anttila MI. Influence of age on toremifene pharmacokinetics. Cancer Chemother Pharmacol 1997; 40 (2): 185-8
52. Wiseman H, Lewis DFV. The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modeling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. Carcinogenesis 1996 Jun; 17 (6): 1357-60
53. Berthou F, Dreano Y, Belloc C, et al. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 1994 May; 47 (10): 1883-95
54. Meltzer NM, Stang P, Stemson LA. Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes. Biochem Pharmacol 1984 Jan; 33 (1): 115-23
55. Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 1980 Jun-Jul; 64 (6-7): 761-4
56. Dehal SS, Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 1999 Jun; 27 (6): 681-8
57. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982 Jan; 42 (1): 317-23
58. Kangas L. Biochemical and pharmacological effects of toremifene metabolites. Cancer Chemother Pharmacol 1990; 27 (1): 8-12
59. Bishop J, Murray R, Webster L, et al. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 1992; 30 (3): 174-8
60. Ducharme J, Fried K, Shenouda G, et al. Tamoxifen metabolic patterns within a glioma patient population treated with highdose tamoxifen. Br J Clin Pharmacol 1997 Feb: 43 (2): 189-93
61. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25 (2): 127-205
62. McVie JG, Simonetti GP. Stevenson D, et al. The bioavailability of Tamoplex (tamoxifen): Pan 1. a pilot study. Methods Find Exp Clin Pharmacol 1986 Aug; 8 (8): 505-12
63. Knadler MP, Lantz RJ, Gillespie TA. et al. The disposition and metabolism of 14C-labeled raloxifene in humans [abstract]. Pharm Res 1995; 12 Suppl. 1: 372
64. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Cancer 1999 Jul; 85 (1): 23-9
65. Sutherland CM, Sternson LA, Muchmore JH, et al. Effect of impaired renal function on tamoxifen. J Surg Oncol 1984 Dec: 27 (4): 222-3
66. DeGregorio MW, Wiebe VJ, Venook AP, et al. Elevated plasma tamoxifen levels in a patient with liver obstruction. Cancer Chemother Pharmacol 1989; 23 (3): 194-5
67. Peyrade F, Frenay M. Etienne MC, et al. Age related difference in tamoxifen disposition. Clin Pharmacol Ther 1996 Apr; 59 (4): 401-10
68. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin [letter]. BMJ 1989 Jan; 298 (6666): 93
69. Kivistö KT, Villikka K, Nyman L, et al. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998 Dec: 64 (6): 648-54
70. Lien EA, Lønning PE, Solheim E, et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 1990 Sep; 50 (18): 5851-7
71. Dowsett M, Pfister C, Johnston SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999 Sep; 5 (9): 2338-43
72. Ingle JN, Suman VJ, Johnson PA, et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999 Jul; 5 (7): 1642-9
73. Miller JW, Skerjanec A, Knadler MP, et al. Divergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res 2001 Jul; 18 (7): 1024-8